

# Veeda Oncology

Proven Capabilities to support  
Advanced Early to Late Phase  
Oncology Clinical Trials

---

Partners in creating a healthier tomorrow

---

## Team's Experience and Capabilities

The team at Veeda has wide experience in handling complex early and late-phase Oncology studies in an efficient, quick, and compliant manner across indications.

Our team has expertise in handling studies in specific cancers such as Non-Hodgkin's Lymphoma (NHL), Prostate, Non-small-cell lung carcinoma (NSCLC), Ovarian, Metastatic Breast Cancer (MBC), etc., with an involvement in full clinical development program for certain drugs like Bevacizumab, Docetaxel, Trastuzumab, Rituximab and Paclitaxel across multiple indications. With This expertise, we are able to ensure that the myriad complexities associated with Oncology studies are considered right from the planning stage.

| Veeda's Team Experience                 |           |                 |
|---|-----------|-----------------|
| Study Molecule                          | Phase     | No. of patients |
| Rituximab                               | Phase-III | 100             |
| Azacitidine                             | Phase-IV  | 60              |
| Bevacizumab                             | Phase-IV  | 268             |
|   | Phase III | 129             |
| Bevacizumab V/s Avastin                 | Phase III | 594             |
| Cabazitaxel (4 studies)                 | POC       | 200             |
| Cetuximab                               | Phase III | 129             |
| Denosumab                               | Phase III | 150             |
| FDC – Capecitabine and Cyclophosphamide | Phase III | 166             |
| Goserelin 3.6 mg Injection              | Phase III | 68              |
| Goserelin Acetate Implant (10.8 mg)     | Phase III | 210             |
| Liposomal Docetaxel                     | Phase-IV  | 86              |
|   | Phase-IV  | 50              |
|   | Phase-IV  | 50              |
|   | Phase-IV  | 50              |
| Liposomal Paclitaxel (2 studies)        | Phase III | 200             |
| NCE (Endoxifen)                         | Phase II  | 34              |
| NCE (PNB 028)                           | Phase I   | 24              |
| Trastuzumab                             | Phase III | 500             |
|   | Phase-IV  | 200             |
|   | Phase III | 120             |
| Docetaxel Injection                     | Phase III | 657             |

## A Closer look at Veeda's Oncology Study Experience



| Veeda's Experience   |                                      |
|----------------------|--------------------------------------|
| Molecule Names       | Study & Submission Details           |
| Bortezomib           | Patient PK study; USFDA              |
| CA-170               | Phase II study; USFDA                |
| Capecitabine         | Patient PK studies; USFDA            |
| Docetaxel            | Patient PK study; USFDA & China NMPA |
| Doxorubicin          | Patient PK studies; USFDA & EMA      |
| Etoposide            | Patient PK study; USFDA              |
| Everolimus           | Patient PK studies; USFDA            |
| Imatinib             | Patient PK studies; USFDA & EMA      |
| Leuprolide acetate   | Patient PK study; USFDA              |
| Paclitaxel           | Patient PK studies; USFDA            |
| <b>Total Studies</b> | <b>24</b>                            |

## Access to a vast network of KOLs enabling us to undertake complex Oncology Clinical Trials

With our network and prior experience, we can provide access to trusted Key Opinion Leaders (KOLs), in the area of Oncology. With our expertise in Oncology trials and our collaboration with specialists, we already have derived an extensive network of contacts, including investigators, surgical oncologists, radiation oncologists, and medical oncologists. We are also associated with some of the most prestigious hospitals recruiting patients for cancer. As a result, we are able to offer our clients the best settings for their oncology clinical trials and provide the services and solutions they need for the trial to succeed.



## Identifying the Right Investigators and Patients for Oncology Trials

We have an established pool of investigators (350+ oncologists) across 120 sites in India and site relationships to ensure rapid identification of potential investigators and patient populations to help ensure enrollment goals are met.




## Our Regulatory Credentials

### Key to Guiding sponsors through an ever-evolving landscape

Our team's expertise in handling Oncology trials along with regulatory modifications aimed at accelerating the development and approval of cancer drugs has helped our sponsors' breakthroughs reach patients more quickly.

Our vast global regulatory experience with the **USFDA, EMA, Health Canada, MHRA, ANVISA, WHO, NPRA Malaysia, ANSM, AGES, MCC, and DCGI** helps us successfully guide sponsors through the ever-evolving regulatory landscape.

## Navigating the Regulatory Pathway in India



## Our Team's Experience

Oncology clinical trials require sites to be monitored, and the CRA team has an average of **7 years** of experience in ensuring that project plans are implemented as assigned

With an average of **11 years** of rich experience of CTL team, we are able to establish, cultivate, and maintain scientific relationships with investigators and study coordinators to support enrollment while developing a strong understanding of clinical practice


With around **12 years** of average team experience, our clinical project management team provides dedicated support to the sponsors from the start to the end of the project


## Our Approach for Patient Recruitment, Retention & Site Selection

We can help you identify the best strategy to mitigate costs, risks, and identify the best sites providing meaningful insight into your recruitment challenges, evaluating the impact of competitive trials, and optimizing patient access and retention.

- **Sound understanding of operational nuance in Oncology** studies including site and patient-level considerations
- **Rapid study start-up:** Our team quickly identifies and activates qualified credentialed and motivated sites. Our insights-driven site selection and feasibility services together with our site budgeting and contracting services solve common trouble spots in the start-up of clinical trials, **helping sponsors compress their study timelines by 33%**
- **Patient recruitment and retention:** By utilizing the most appropriate communication channels the team at Veeda helps sponsors overcome patient recruitment & retention challenges by focusing recruitment efforts where they are needed most: at the site level. By combining a dedicated study team with a customized site recruitment strategy, enrolment becomes focused, effective, and streamlined so that clinical studies begin and stay on schedule
- **Relationship with leading Oncology centres, key opinion leaders, and investigators**, which can support recruitment strategy

## Our Global Foot Print



 Serving clients across these geographies

 Veeda's Team Presence

To know more about  
our Oncology Clinical Trial Capabilities, mail us at  
[info@veedacr.com](mailto:info@veedacr.com)

Partners in creating a healthier tomorrow

 +91 79 6777 3000

 [www.veedacr.com](http://www.veedacr.com)